Tags

Type your tag names separated by a space and hit enter

Perspectives of stem cell therapy in Duchenne muscular dystrophy.
FEBS J. 2013 Sep; 280(17):4251-62.FJ

Abstract

Muscular dystrophies are heritable and heterogeneous neuromuscular disorders characterized by the primary wasting of skeletal muscle, usually caused by mutations in the proteins forming the link between the cytoskeleton and the basal lamina. As a result of mutations in the dystrophin gene, Duchenne muscular dystrophy patients suffer from progressive muscle atrophy and an exhaustion of muscular regenerative capacity. No efficient therapies are available. The evidence that adult stem cells were capable of participating in the regeneration of more than their resident organ led to the development of potential stem cell treatments for degenerative disorder. In the present review, we describe the different types of myogenic stem cells and their possible use for the progression of cell therapy in Duchenne muscular dystrophy.

Authors+Show Affiliations

Laboratorio Cellule Staminali, Dipartimento di Fisiopatologia medico-chirurgica e dei Trapianti, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

23206279

Citation

Meregalli, Mirella, et al. "Perspectives of Stem Cell Therapy in Duchenne Muscular Dystrophy." The FEBS Journal, vol. 280, no. 17, 2013, pp. 4251-62.
Meregalli M, Farini A, Belicchi M, et al. Perspectives of stem cell therapy in Duchenne muscular dystrophy. FEBS J. 2013;280(17):4251-62.
Meregalli, M., Farini, A., Belicchi, M., Parolini, D., Cassinelli, L., Razini, P., Sitzia, C., & Torrente, Y. (2013). Perspectives of stem cell therapy in Duchenne muscular dystrophy. The FEBS Journal, 280(17), 4251-62. https://doi.org/10.1111/febs.12083
Meregalli M, et al. Perspectives of Stem Cell Therapy in Duchenne Muscular Dystrophy. FEBS J. 2013;280(17):4251-62. PubMed PMID: 23206279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Perspectives of stem cell therapy in Duchenne muscular dystrophy. AU - Meregalli,Mirella, AU - Farini,Andrea, AU - Belicchi,Marzia, AU - Parolini,Daniele, AU - Cassinelli,Letizia, AU - Razini,Paola, AU - Sitzia,Clementina, AU - Torrente,Yvan, Y1 - 2013/01/07/ PY - 2012/10/01/received PY - 2012/10/30/revised PY - 2012/10/31/accepted PY - 2012/12/5/entrez PY - 2012/12/5/pubmed PY - 2013/10/25/medline KW - Duchenne muscular dystrophy KW - stem cells KW - therapy SP - 4251 EP - 62 JF - The FEBS journal JO - FEBS J. VL - 280 IS - 17 N2 - Muscular dystrophies are heritable and heterogeneous neuromuscular disorders characterized by the primary wasting of skeletal muscle, usually caused by mutations in the proteins forming the link between the cytoskeleton and the basal lamina. As a result of mutations in the dystrophin gene, Duchenne muscular dystrophy patients suffer from progressive muscle atrophy and an exhaustion of muscular regenerative capacity. No efficient therapies are available. The evidence that adult stem cells were capable of participating in the regeneration of more than their resident organ led to the development of potential stem cell treatments for degenerative disorder. In the present review, we describe the different types of myogenic stem cells and their possible use for the progression of cell therapy in Duchenne muscular dystrophy. SN - 1742-4658 UR - https://www.unboundmedicine.com/medline/citation/23206279/Perspectives_of_stem_cell_therapy_in_Duchenne_muscular_dystrophy_ L2 - https://doi.org/10.1111/febs.12083 DB - PRIME DP - Unbound Medicine ER -